Lisinopril Market - By Dosage (Tablet, Liquid), Dosage Strength (10 Mg, 20 Mg, 25 Mg), Patient Age Group (Children, Adult), Application (Hypertension, Heart Failure, Heart Attack, Diabetic Kidney Disease), Distribution Channel – Global Forecast (2024 – 2032)

Lisinopril Market Size

Lisinopril Market size was valued at around USD 1.5 billion in 2023 and is estimated to grow at 4.8% CAGR from 2024 to 2032. Lisinopril is a medication primarily used to treat high blood pressure and heart failure. It belongs to a class of drugs called angiotensin-converting enzyme (ACE) inhibitors. Lisinopril works by relaxing blood vessels helps to lower blood pressure and improve blood flow to the heart. It's typically taken orally once daily.
 

The growing prevalence of cardiovascular diseases is a significant driver for lisinopril market. For instance, according to the National Library of Medicine, in January 2023, coronary artery disease (CAD) accounted for approximately 6,10,000 deaths annually (estimated 1 in 4 deaths) and is the leading cause of mortality in the U.S. Also, it is the third leading cause of mortality worldwide and is associated with 17.8 million deaths annually. Thus, this underscores the critical importance of medications such as lisinopril in managing cardiovascular conditions and reducing mortality rates.
 

Furthermore, increasing aging population, growing awareness and screening programs, and innovations in drug delivery are contributing factors stimulating the growth of the market.
 

Lisinopril Market Trends

Innovations in novel drug delivery systems are reshaping the field of cardiovascular therapeutics, impacting medications such as lisinopril, commonly prescribed for hypertension and heart failure. This transformative shift comes at a critical time as cardiovascular diseases become more prevalent worldwide due to aging populations and lifestyle shifts. Consequently, there is a growing need for enhanced and patient-centric drug delivery approaches to meet the rising demand for effective treatments.
 

• Developing extended-release formulations of lisinopril could allow for once-daily dosing, providing sustained blood pressure control over a longer duration. This could improve patient adherence and convenience while minimizing fluctuations in blood pressure levels.
   
• While lisinopril is typically administered orally, intravenous formulations could offer a rapid onset of action, making them suitable for acute management of hypertension or heart failure in hospitalized patients. Intravenous delivery may also be beneficial for patients with difficulty swallowing or those require immediate blood pressure reduction.
   
• Nanotechnology-based drug delivery, which is estimated to reach USD 308.4 billion by 2032, systems such as nanoparticles or liposomes, could enhance the bioavailability and tissue targeting of lisinopril. These nano formulations could improve drug solubility, stability, and cellular uptake, potentially allowing for lower doses and reduced side effects. Thus, escalating the growth of the market.
   

Lisinopril Market Analysis

Based on dosage, the market is divided into tablet and liquid. The tablet segment is estimated to account for USD 1.9 billion by 2032.
 

• Tablets are easy to administer and can be taken orally with water, making them convenient for patients to incorporate into their daily routines. This simplicity enhances patient adherence to treatment regimens, is crucial for achieving optimal therapeutic outcomes.
   
• Lisinopril tablets are available in various strengths, allowing healthcare providers to tailor the dosage to the individual patient's needs. This flexibility enables precise titration of the medication, optimizing blood pressure control while minimizing the risk of side effects.
   
• Additionally, tablet formulations of lisinopril typically have a long shelf life and remain stable under normal storage conditions. This stability ensures that the medication retains its potency and efficacy over time, reducing the likelihood of dose variability or degradation.
   

Based on dosage strength, the lisinopril market is bifurcated into 10 mg, 20 mg, and 25mg. The 20 mg segment accounted for USD 573.6 million in 2023.
 

• The 20 mg dosage of lisinopril is often considered the standard maintenance dose for many patients with hypertension. It provides sufficient potency to effectively lower the blood pressure levels, helping to achieve target goals and reduce the risk of cardiovascular complications.
   
• For patients requiring higher doses of lisinopril to achieve adequate blood pressure control, the 20 mg tablet allows for a streamlined dosing regimen compared to taking multiple lower-strength tablets. This can improve patient adherence and convenience, as well as reduce the risk of medication errors.
   
• Additionally, in many healthcare systems the 20 mg strength of lisinopril may be more cost-effective than higher doses or alternative medications. Its availability as a generic medication further enhances its affordability, making it a preferred choice for both patients and healthcare providers.
   
• Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on patient age group, the lisinopril market is divided into children and adults. The adults segment is estimated to account for USD 1.8 billion by 2032.
 

• Lisinopril is a well-established medication with a strong track record of effectively lowering blood pressure in adults. Clinical studies have demonstrated its efficacy in reducing both systolic and diastolic blood pressure, thereby lowering the risk of cardiovascular events such as heart attacks and strokes.
   

• In addition to its antihypertensive effects, lisinopril has cardioprotective properties that can benefit adults with certain heart conditions. It has been shown to reduce the risk of heart failure progression, improve left ventricular function, and decrease mortality in patients with heart failure following a myocardial infarction.
   

Based on application, the lisinopril market is classified into hypertension, heart failure, heart attack, diabetic kidney disease, and other applications. The heart attack segment accounted for USD 113.5 million in 2023.
 

• Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor, works by relaxing blood vessels, thereby reducing blood pressure. Lowering blood pressure is crucial in preventing heart attacks, especially in individuals with hypertension, as it decreases the workload on the heart and reduces the risk of plaque rupture in the arteries.
   
• Lisinopril may have beneficial effects on the stability of atherosclerotic plaques in the arteries. By reducing inflammation and oxidative stress, lisinopril may help stabilize vulnerable plaques, are more prone to rupture and cause a heart attack. Thus, all these aforementioned factors are expected to drive segmental growth.
   

Based on distribution channel, the lisinopril market is divided into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is estimated to account for USD 911.1 million by 2032.
 

• Lisinopril is considered a first-line therapy for the management of hypertension and heart failure, as well as a component of standard post-myocardial infarction therapy. Its established efficacy and safety profile position it as a cornerstone medication in the treatment guidelines endorsed by professional medical associations.
   
• Lisinopril is often included in hospital formularies due to its cost-effectiveness, widespread use, and established clinical benefits. Its availability as a generic medication further enhances its appeal for formulary inclusion, offering hospitals an affordable option for cardiovascular therapy.
   
• Hospital pharmacies often work closely with interdisciplinary healthcare teams to optimize medication therapy and patient outcomes. Lisinopril provides an opportunity for pharmacists to collaborate with physicians, nurses, and other healthcare professionals in developing and implementing comprehensive treatment plans for patients with cardiovascular conditions.
   

The lisinopril market in U.S. accounted for a significant revenue of USD 631.4 million in 2023, and this trajectory is set to continue upwards.      
 

• The increasing prevalence of hypertension and cardiovascular diseases has emerged as a significant driver in the U.S. market. For instance, according to Centers for Disease Control and Prevention (CDC) in 2021 coronary heart disease emerged as the leading cause of heart-related fatalities, claiming the lives of 375,476 individuals, approximately 1 in every 20 adults aged 20 and above grapples with coronary artery disease (CAD), the most prevalent form of heart disease.
   
• The U.S. is at fore front in medical research with renowned institutions actively involved in drug development and clinical trials. This fosters a continuous improvement of lisinopril formulations and potential discovery of new applications.
   

The lisinopril market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany boasts a well-established and robust pharmaceutical industry, known for its research, development, and manufacturing capabilities. This could give German companies a competitive edge in terms of production costs and innovation within the market.
   

Japan lisinopril market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan has stringent regulatory standards for pharmaceuticals, ensuring the safety and efficacy of drugs. Companies that meet these standards can gain trust both domestically and internationally, potentially giving Japanese lisinopril manufacturers a competitive edge.
   

The lisinopril market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The Saudi government has been making substantial investments in its healthcare infrastructure to meet the needs of its growing population. This includes expanding hospitals, clinics, and pharmacies, which in turn increases the demand for essential medications like lisinopril.
   

Lisinopril Market Share

The lisinopril industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Lisinopril Market Companies

Some of the eminent market participants operating in the lisinopril industry include:

• AbbVie Inc.
• Amneal Pharmaceutical, Inc.                              
• AstraZeneca                      
• Apotex Inc.                        
• Aurobindo Pharma Ltd.                            
• Bausch Health Companies, Inc.                          
• Cipla Limited                      
• Hikma Pharmaceutical PLC.                     
• Lupin Limited                     
• Merck & Co., Inc.                          
• Pfizer Inc.                          
• Sun Pharmaceutical Industries Limited                          
• Teva Pharmaceutical Industries Limited                         
• Vitaris Inc.                         
• Zydus Lifesciences Limited
   

Lisinopril Industry News:

• In April 2021, Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv Specialty Pharmaceuticals, LLC. This strategic decision broadened Amneal's portfolio, incorporating a more extensive array of branded products and complex generics, while strengthening its position in the medication market and opening avenues for innovation and growth within the industry.
   

The lisinopril market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Dosage

• Tablet
• Liquid

Market, By Dosage Strength

• 10 Mg 
• 20 Mg 
• 25 Mg

Market, By Patient Age Group

• Children
• Adults

Market, By Application

• Hypertension
• Heart failure 
• Heart attack  
• Diabetic kidney disease      
• Other applications       

Market, By Distribution Channel

• Hospital pharmacy   
• Retail pharmacy      
• Online pharmacy          

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa